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Peripartum cardiomyopathy (PPCM) is a rare entity, and anesthetic management 
for cesarean section of a patient with this condition can be challenging. We hereby 
present the anesthetic management of a patient with PPCM complicated with pre-
eclampsia scheduled for cesarean section, along with a mini review of literature. A 
24 year-old primigravida with twin gestation was admitted to our hospital with se-
vere PPCM and preeclampsia for peripartum care, which finally required a cesare-
an section. Preoperative optimization was done according to the goal of managing 
left ventricular failure. Combined spinal epidural (CSE) anaesthesia with bupiva-
caine and sufentanil was used for cesarean section under optimal monitoring. The 
surgery was completed without event or complication. Postoperative pain relief 
was adequate and patient required only one epidural top up with sufentanil 6 hours 
after operation. To the best of our knowledge there is no report in literature of the 
use of sufentanil as a neuraxial opioid in the anesthetic management of cesarean 
section in a patient with PPCM. CSE with sufentanil may be a safer and more ef-
fective alternative in such cases. 
Key Words:      Peripartum cardiomyopathy, anesthetic management, combined spi-
nal epidural, sufentanil, literature review 
INTRODUCTION
Peripartum cardiomyopathy (PPCM) is by definition a primary myocardial disease 
without any demonstrable cause and having onset during the last month of preg-
nancy or in the first five months after delivery.1 Echocardiographic features of left 
ventricular dysfunction were added to the modified definition later to make it more 
precise (Table 1).2,3 PPCM may be associated with preeclampsia and the clinical 
scenario can worsen heart failure.1,4-20 Anesthetic management of cesarean section 
in PPCM patients can be a challenge to the anesthesiologist.5,8,10,21,22 Correct choice Pradipta Bhakta, et al.
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ultrasonogram) and progressive deterioration of cardiac sta-
tus and liver function tests (LFT) (Table 3), a decision was 
made to electively terminate the pregnancy by cesarean 
section. 
Preanaesthetic examination revealed pulse rate (PR), 
blood pressure (BP), peripheral oxygen saturation (SpO2) 
and respiratory rate of 80 beats/min, 90/70 mmHg, 90% on 
room air and 15/min, respectively. The chest was found to 
be clear on auscultation. Examination of the cardiovascular 
system (CVS) showed a third heart sound and an ejection 
systolic murmur in the mitral area. The preoperative echo-
cardiogram showed dilated cardiac chambers, global hypo-
kinesia with a left ventricular ejection fraction (LVEF) of 
25% and moderate pulmonary arterial hypertension (PAH) 
(Table 2). Significant laboratory investigations were border-
line derangement in LFT, coagulation parameters, marginal 
leucocytosis and platelet count of 98 × 109/L (Table 3). The 
anesthetic plan of performing the procedure under com-
bined spinal epidural (CSE) after optimization of cardio-
vascular and coagulation status was discussed with the par-
ent team and the patient, who gave informed consent.  
The preoperative optimization process was initiated. In-
vasive arterial and central venous accesses were estab-
lished. Dopamine and dobutamine infusions were started 
and titrated to optimize her cardiovascular variables. She 
received fresh frozen plasma (FFP) for correction of her co-
agulation status. Intravenous ranitidine (50 mg) and meto-
clopramide (10 mg) and oral sodium citrate solution (0.3 
M, 30 mL) were given 30 minutes before transferring her to 
the operating room (OR). Standard ASA monitors along 
with invasive blood pressure (IBP), central venous pressure 
(CVP) and urine output were used for intraoperative moni-
toring. Oxygen was administered via facemask at 4 L/min. 
Her preoperative heart rate (HR), mean arterial pressure 
(MAP), CVP, and SpO2 were 108/min, 65 mmHg, 15 
mmHg and 94%.
of anesthesia and precise titration is crucial for a favorable 
outcome. We present the anesthetic management of such a 
patient along with a small relevant literature review. 
 
CASE REPORT   
A twenty-four year-old primigravida weighing fifty kilo-
gram (kg) was admitted to a cardiac center at thirty-two 
weeks of gestation with complaints of increasing breath-
lessness and generalized swelling for two weeks without 
any prior coexisting medical illnesses. She was diagnosed 
with peripartum cardiomyopathy complicated with pre-
eclampsia based on clinical and echocardiographic findings 
(Table 2) and was put on oral digoxin 0.25 mg (five days a 
week), furosemide 40 mg once daily, carvedilol 3.125 mg 
twice daily and potassium supplements. She was referred to 
our hospital for further management. 
Treatment was started in the intensive care unit by a mul-
tidisciplinary team of physicians with a plan to control her 
heart failure medically and to induce fetal lung maturation 
by dexamethasone before elective delivery.12 Because of in-
trauterine death (IUD) of one fetus (as revealed by repeat 
Table 1. Modified Diagnostic Criteria of PPCM
1-3
Diagnostic criteria for PPCM
  Heart failure within the last month of pregnancy or
  six month postpartum
Absence of prior heart disease
No determinable cause
Echocardiographic evidence of left ventricular 
  dysfunction:
LVEF < 45%
LVFS < 30%
LVEDD < 2.7 cm/m
2 body surface area
LVEF, left ventricular ejection fraction; LVFS, left ventricular fractional 
shortening;  LVEDD,  left ventricular end diastolic diameter.
Table 2. Echocardiographic Findings of Peri-Partum Cardiomyopathy
Time of 
echocardiography
Left ventricular 
ejection fraction
Other findings
Preoperative 
Echocardiography 
(12,02,06)
25 - 30%
Dilated cardiomyopathy, Severe global hypokinesia, 
Severe MR, mild TR, trace AR, Dilated all cardiac 
Chambers, No intracardiac clot. Moderate PAH.
Postoperative 
Echocardiography (6th 
post-op day)
25%
Generalized severe LV & RV hypokinesia, dilated 
all four chambers, low velocity grade 3/3 MR, grade 1/3 
TR, pulmonary artery pressure 34 mmHg, no LV/LA 
clot, LV stasis present, severe LV diastolic dysfunction.
MR, mitral regurgitation; TR, tricuspid regurgitation; AR, aortic regurgitation; PAH, pulmonary arterial hypertension; LV, left ventricle; RV, 
right ventricle; LA, left atrium. Severe Peripartum Cardiomyopathy Complicated with Pre-Eclampsia
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Urine output was 75 mL without any episode of adverse 
hemodynamic events. Intraoperative parameters like heart 
rate (HR), mean arterial pressure (MAP), CVP and SpO2 
remained within 20% of the preoperative value. 
The patient was transferred back to the ICU after the pro-
cedure. She remained absolutely pain free for the next six 
hours and the EC was removed after administration of 20 
µg of sufentanil in 10 mL NS. Furosemide and digoxin 
were restarted and FFP transfusion was continued q6h for a 
day with close monitoring of coagulation profile. Clinical 
improvement was evident from post-operative day (POD) 
2, with a decrease in ionotrope requirement and an im-
provement in LFT. Patient had mild dyspnea on POD 3 and 
a chest radiograph showed signs of pulmonary edema, 
which was relieved by furosemide. Gradually she was 
weaned off dobutamine completely and restarted on carve-
dilol. Oral captopril 6.25 mg, spironolactone 25 mg once 
daily and DVT prophylaxis with 5,000 U unfractionated 
heparin were added on POD 4. The remainder of her post-
operative stay was uneventful. Her LFT, serum creatinine, 
and uric acid levels showed a decreasing trend correspond-
ing with her improved clinical condition (Table 3). Repeat 
echocardiography on POD 6 showed severe generalized 
left and right ventricular hypokinesia with further reduction 
in ejection fraction to less than 25% (Table 2).
She was later transferred back to the cardiac center, 
where she underwent placement of temporary pacemaker 
The CSE technique consisted of sitting position and mid-
line approach at L3-L4 interspace. The epidural space was 
identified by loss of resistance to saline on the first attempt 
with an 18G Tuohy needle (Portex). A subarachnoid block 
(SAB) was done by 27G Whitacre needle by needle 
through needle technique and 1.2 mL of 0.5% heavy bupi-
vacaine (6 mg) with 7.5 µg of sufentanil was injected after 
free flow of cerebrospinal fluid (CSF). An 18 gauge epidur-
al catheter (EC) was threaded up to the length of four cm 
into epidural space. A fifteen cm wedge was placed under 
the left hip to maintain a left lateral tilt. Level of block (re-
sponse to ice cube) was checked at 3, 5 and 10 minutes and 
was found to be up to thoracic 10th, 8th, 6th segment level 
respectively. Effective onset of block resulted in some im-
provement of MAP, SpO2 and clinical symptoms. Surgery 
went ahead without event and both the living baby and 
dead fetus were delivered. Apgar scores of the baby at 1 
and 5 minutes were 7 and 9 respectively. Intravenous oxy-
tocin drip (15 units/500 mL of saline at 40 drops/min) was 
started slowly after delivery. Intravenous furosemide 10 mg 
and midazolam 2 mg were given incrementally at this time. 
Dopamine and dobutamine infusions were continued 
throughout the surgery titrated to the hemodynamics. The 
total estimated blood loss was about 250 mL during the 
hour-long procedure. Intravenous fluid replacement was 
targeted to maintain the CVP of 12 to 14 mmHg, and 750 
mL of Ringer’s Lactate (RL) was given intraoperatively. 
Table 3. Serial Laboratory Investigations and Subsequent Results for the Case Study Patient
Investigation Pre-op
Day of 
operation
Post-op 
Day 2
Post-op 
Day 4
Post-op 
Day 6
Hemoglobin (10 - 14 gm/dL)      12.6     10.3   9.2   10.5
TLC (4-11 × 10
9/L) 13.6 × 10
9 14.9 × 10
9 11.4 × 10
9 10.1 × 10
9
Platelet count (150-450 × 10
9/L)    98 × 10
9 134 × 10
9    92 × 10
9  120 × 10
9
Prothrombin time (11.2 - 15.6 sec)     16.2    15 14.0
INR (0.8 - 1.2)       1.25     1.05
APTT (24 - 38 sec)      39    36.5         40
Blood Urea (2.1 - 7.1 mmol/L)     12.29     12.65   10.64
Serum Creatinine (44 - 150 µmol/L)     88.40     88.40   79.56
Uric Acid (179 - 476 µmol/L)   737.80 208.25
Serum Sodium (135 - 145 mmol/L)   132.1  133 133.6       133.1 135.1
Serum Potassium (3.5 - 5 mmol/L)       4.6      3.9       3.7   3.8     4.9
Serum Bilirubin (5.13 - 17.1 µmol/L)     32.49     23.94     20.52
AST (0.18 - 0.78 µkat/L)       3.95       1.73       1.30
ALT (0.12 - 0.88 µkat/L)       8.58       4.45       2.08
ALP (0.63 - 2.10 µkat/L)       4.45       3.13       2.95
TLC, total leucocyte count; INR, international normalization ratio; APTT, activated partial thromboplastin time; AST, aspartate amiotrans-
ferase; ALT, alanine aminotransferase. Pradipta Bhakta, et al.
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agree that PPCM commonly occurs in twin pregnan-
cies.1,4,5,8,9,13,14,20,25,26,28,37 Preeclampsia and hypertension has 
been frequently reported to be associated with PPCM cas-
es.1,4-20 The similarities in immunopathologic process in-
volving prolactin, matrix-metalloproteinase (MMP) and 
graft vs. host reaction between preeclampsia and PPCM 
strongly support this association.19,47-49 Some authors even 
described it as a hypertensive heart failure and described it 
as a significant risk factor for PPCM.6,16,44 Initially, breast 
feeding, malnutrition, poor socioeconomic condition and 
antenatal care were implicated as risk factors;1,5,38 however,   
no such correlations have been found in recent reports.5,7,37 
Likewise, although substance abuse and familial occur-
rence have been causally implicated,2,10,11,37 they should be 
regarded as a variety of cardiomyopathy.5,8 All the reported 
risk factors are quite old, predating modified definition and 
echocardiography. Thus, further evaluation will be neces-
sary, keeping in mind advances in medical technology.5,10
Proper etiology of PPCM is unclear and several etiolo-
gies such as inflammation (myocarditis, cytokines), viral 
infection, autoimmunity, abnormal response to the hemody-
namic stress of pregnancy, cytokine-mediated inflamma-
tion, Gq-related myocyte apoptosis, oxidative stress-in-
duced Cathepsin D production which produces defective 
prolactin leading to endothelial damage and apoptosis of 
vascular cells, prolonged tocolysis, and selenium deficiency 
have been proposed.1-11,13,15,16,19,25,28-31,33,35-38,40,46-52 There is 
stronger literary evidence to support inflammation, viral in-
fection, 16 kDa prolactin induced apoptosis and autoimmu-
nity as possible etiology of PPCM.2,3,5,6,9,13,19,25,27,29-31,33,34,36,37,46-52 
Thus, it is more likely that etiology is multifactorial.7,13,25,28,33 
New targeted research directing towards inflammatory, vi-
ral, prolactin and autoimmune etiologies are needed using 
modern molecular and biochemical techniques to find out 
actual reason behind PPCM.13,25,37
PPCM clinically presents with orthopnea, dyspnea upon 
exertion, palpitation, chest pain, headache, cough and mal-
aise suggestive of left ventricular failure.1-8,12,14,21-31,36,39-42,45 
The majority of patients present with severe heart failure 
[New York Heart Association (NYHA) physical class III or 
IV].7,8,14,18,25,27,34,36 However, the actual categorization used 
by NYHA in advanced pregnancy can be confounded by 
the physiological changes of pregnancy.20,30,31 Ventricular 
and supraventricular tachyarrhythmias, intracardiac throm-
bi, features of systemic embolism such as chest pain, hae-
moptysis and hemiplegia due to acute myocardial infarc-
tion, pulmonary and cerebral embolism, infarction of the 
for resistant bradyarrhythmia with some symptomatic im-
provement without any change in echocardiographic find-
ings. As per the latest verbal information from cardiac cen-
ter, she continues to have features of moderate ventricular 
dysfunction while the baby is doing fine. She was strongly 
advised against any future pregnancies. 
 
DISCUSSION
PPCM is a severe form of heart failure which was first de-
scribed by Demakis and Rahimtoola1 comprising of 3 crite-
ria; namely, 1) Development of heart failure in the last month 
of pregnancy or within the first 5 months of postpartum, 2) 
Absence of any determinable cause of cardiac failure and/or 
3) Any prior demonstrable heart disease. Later, echocardio-
graphic evidence of left ventricular dysfunction was added 
by the PPCM workshop committee of the National Institute 
of Health (NIH) (Table 1).2,3 The time period in the definition 
was specified to exclude congenital and acquired causes of 
heart failure which may as well be present in the earlier stag-
es of pregnancy although some cases of PPCM have been re-
ported to occur outside this time limit.1,2,5,7-9,11,13,21-27 Although 
the earlier reported incidence was 1 in every 3,000 to 15,000 
live births,1,4,5 more recently reported incidence in the USA 
was about 1 in every 1,485-4,000 pregnancies, thus indicat-
ing an increasing trend, and even more so in African-Ameri-
cans.2,5,7,8,14-16,25,28-32 This increased incidence may be due to 
better health awareness and improved diagnostic modali-
ties.27 But PPCM appears to occur more frequently in Haiti 
(1 in 300 live births)25 and in Africa (1 in 100 to 1,000 live 
births).6,9,25 A proper explanation for this much higher inci-
dence of PPCM in some geographic areas is not yet known. 
Environmental or genetic factors, local cultural habits and re-
porting, as well as diagnostic bias, may be some reasons for 
this higher incidence.6,14,15,18-20,32-34
Several risk factors that have been correlated to PPCM are: 
advanced maternal age, multiparity, multiple gestation, black 
race, African-American female, malnutrition, hypertension, 
preeclampsia, alcohol, cocaine and tobacco abuse, poor ante-
natal care, low socioeconomic condition, breast feeding and 
positive family history.1-11,13-18,20,25-30,32,35-40 Although PPCM 
has been reported to occur classically in cases with higher 
maternal age, parity and African race;1-10,15,21,22,25,32,36-39,41 re-
cently it has been found to occur increasingly in younger 
age groups, and in primigravida and white mothers as 
well.5-11,13,14,16,17,19,20,22,23,25,32,35,41-46 Most of the researchers Severe Peripartum Cardiomyopathy Complicated with Pre-Eclampsia
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who do not respond to standard heart failure manage-
ment.27,54 The detection of DGE in order to detect myocardial 
fibrosis has been indicated as a good prognostic factor.27,53 
Cine MRI can be used as an alternative to detect all the pa-
rameters like echocardiography.54 Currently, routine use of en-
domyocardial biopsy is somewhat controversial.5,8,10,25,30,37 It 
may be considered if the patient does not improve after two 
weeks of conventional management.5,7,9,25,28,37 Routine hae-
matological, biochemical, serological and blood culture stud-
ies are used to rule out other causes of heart failure.4,5,23 Poly-
merase chain reaction and immunohistochemistry techniques 
should be used to rule out viral and autoimmune etiology in 
suspected cases.27,34 Estimation of C-reactive protein (CRP), 
Interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), Fas-
Apo-1, interferon-γ (IFN-γ), and N-terminal-pro Brain na-
triuretic peptide (NT-proBNP, a serum marker of heart fail-
ure), serum prolactin should now be strongly considered in 
light of current evidence of the inflammatory and autoim-
mune nature of PPCM.5,25,27,29,36,46,49,52
Medical therapy for PPCM follows the routine principles 
of management of heart failure and is aimed at reduction of 
preload, afterload and increase in cardiac contractility 
through judicious use of bed rest, salt restriction, diuresis, 
digitalization, vasodilators, β-blockers and anticoagulan-
ts.1,2,4,5,8,10,14,17,25-31,36-42,51 Safety of drugs during pregnancy 
and lactation should be kept in mind.2,31,37 Though strict bed 
rest used to be advised earlier on,1,38 the current recommen-
dation is a gradual increase in activity as tolerated, after the 
initial distressing symptoms are relieved by drugs, as this 
has been shown to improve outcome.1,2,28,30 Salt and fluid 
restriction has been advised only in severe PPCM cas-
es.2,23,25,41 Digoxin is considered safe during pregnancy and 
lactation, but patients should be carefully monitored, espe-
cially when it is used along with diuretics, because parturi-
ents show an increased sensitivity.1,5,25,30,38,55 Diuretics have 
been indicated to relieve symptoms of fluid overload.12,25,27,29 
They are safe when used carefully, but can inadvertently 
cause hypokalemia and hypovolemia, which may lead to 
placental hypo-perfusion.25,36 When combined with conven-
tional medical management, spironolactone has been 
shown to improve outcomes for PPCM patients because of 
its anti-aldosterone action. However, its safety during preg-
nancy has yet to be proven.5,28 Vasodilators are now consid-
ered vital for a positive outcome in PPCM.5,28 Angiotensin-
converting enzyme inhibitors (ACEI) or angiotensin II 
receptor blockers (ARB) are now a mainstay of congestive 
cardiomyopathy management.5,8,25,28,29,31,36,37 They are con-
spleen and kidney, mesenteric artery occlusion, limb gan-
grene, and finally multiorgan failure have all been reported 
as either as presenting symptoms or complications of 
PPCM.1,4-6,8,10,16,20,21,23,25,27,30,31,34,37,39,42  
PPCM is a diagnosis of exclusion after ruling out other 
common causes of heart failure, such as toxic, metabolic, 
ischaemic or valvular heart diseases.1,8,25,27,30,40 Early diagno-
sis of PPCM is difficult because of physiologic changes of 
advanced pregnancy.2,3,5,30,37 Certain complications of preg-
nancy such as anemia, toxemia and amniotic fluid embo-
lism may have similar clinical presentation.5 However, 
PPCM usually presents in postpartum period (72-93%) 
when physiologic changes of pregnancy should be normal-
izing.1,4,5,7,9,17-20,27,31,34,40 Thus, if a patient presents with per-
sistent or worsening congestive heart failure especially in 
puerperium, the possibility of PPCM should always be con-
sidered as delay in diagnosis is often associated with in-
creased morbidity and mortality.2,25,30 A few asymptomatic 
cases of PPCM have also been reported.25,39 Routine inves-
tigations done to confirm the diagnosis are ECG, chest X-
ray (CXR), and Doppler echocardiography.7,30 ECG usually 
shows sinus tachycardia, low voltage complexes, ST-T 
changes, conduction defects, left axis deviation and ventric-
ular hypertrophy.1,2,4,5,12,18,21-23,25,29,30,34,39 Other arrhythmias 
such as supraventricular, ventricular extrasystoles, and ven-
tricular tachycardia may occur.1,4,16,23,34,37,39,42 Common CXR 
findings are cardiomegaly, pulmonary edema and pleural 
effusion.1,4,5,12,21-23,27,29,30,39,41 As CXR features are nonspecif-
ic, routine use of X-ray should be discouraged during preg-
nancy.40 However, absolutely normal ECG and CXR have 
been reported.4,5,29 This makes echocardiography the most 
valuable and confirmatory diagnostic tool.2,27 Patients may 
present features of severe ventricular dysfunction such as 
increased left ventricular end diastolic diameter (LVEDD), 
left ventricular end systolic diameter (LVESD), decreased 
left ventricular fractional shortening (LVFS) and LVEF, right 
ventricular dysfunction, valvular regurgitation, regional wall 
motion abnormality, pulmonary arterial hypertension (PAH) 
as well as intra cardiac thrombi.2,3,5,7-12,18,21-23,25,26,29,30,35,36,39,41-44 
Valvular regurgitant lesions are the consequence of cardiac 
dilatation.5,26 Magnetic resonance imaging (MRI) and com-
puterized topographic scans are more sensitive diagnostic 
tools for detection of cardiac thrombus.5,10 Cardiac MRI has 
become an attractive modality to assess cardiac function 
and to distinguish etiologic nature of PPCM.27,31,53,54 De-
layed gadolinium enhancement (DGE) can help to detect 
inflammatory myocarditis and should be used in patients Pradipta Bhakta, et al.
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tients usually need prophylactic heparin (unfractionated/
fractionated) during the antepartum and heparin/warfarin 
during the post partum period.5,20,21,25,28-31,36,37,40,51
Currently, the role of immunosuppressive therapy (aza-
thioprine and prednisolone) in PPCM is controversial,5,25,37 
but may be considered for patients not responding to con-
ventional management for two weeks and an endomyocar-
dial biopsy reveals myocarditis.2,5,7,25,37,44 Even though the 
role of immunoglobulin has been questioned, it has been 
used successfully in PPCM.28,56 Considering the increasing 
evidence of autoimmunity, it can be tried in refractory cas-
es.5,19,25,28,57 Recently, pentoxifylline, an immunomodulating 
agent, has been shown to improve physical status (NYHA 
class) and LVEF when added with conventional drugs ther-
apy of PPCM.25,28,36,37 Bromocriptine or its congener caber-
golin has recently emerged as the causative treatment of 
PPCM because of emerging evidence of role of 16 kDa 
fragment of prolactin in the causation of PPCM.6,27,30,46,52 
This group of drugs has been shown to improve ventricular 
dysfunction and to encourage normalization of NT-proB-
NP, CRP, NYHA class, and LVEF when given to PPCM 
patients along with standard heart failure therapy, which 
has shown a real prospect for the etiologic treatment of 
PPCM.27,33,46,52 Routine use of bromocriptine may result in 
the suppression of lactation, which may deprive the infant 
of essential nutrition and sometimes cause acute myocardi-
al infarction.58 Moreover, a larger randomized controlled 
trial is needed to comment firmly on bromocriptine’s role in 
PPCM.31 According to current literature, it may be consid-
ered in severe cases.27,33,46,52
Heart transplant is reserved for those young patients re-
sistant to medical treatment with minimal systemic dam-
age.2,5,7-11,25,27,28,30,31,35,37,40,59 Patients with less than 25% of 
LVEF end up requiring heart transplant for survival in first 
or subsequent pregnancies.17 Aggressive measures such as 
an intra aortic balloon pump (IABP), a ventricular assist de-
vice (VAD), veno-atrial bypass, and an extracorporeal mem-
brane oxygenator (ECMO) may be needed in severe cases 
as a bridging measure for heart transplant.5,10,20,23,27,28,31,40,51,59,60 
PPCM in the antepartum period requires management by 
a multidisciplinary team consisting of cardiologists, obste-
tricians and intensivists as the lives of both mother and fe-
tus  are at stake.2,5,12,21,28,37,45,57 Induction of labour is  consid-
ered if patient’s condition worsens despite maximal medical 
management.5,9,21,28,37 Labor analgesia is favored because of 
its ability to reduce sympathetic stress response of labor 
pain.5,42,61,62 Although a graded epidural is most often used 
traindicated during pregnancy because of their teratogenec-
ity; however, they can be considered to treat especially re-
sistant heart failure when the benefit outweigh the risks, or 
after delivery.2,5,8,25,28,30,31,37 These groups of drugs are excret-
ed in milk and may prevent breast feeding if their use is 
warranted.5 During the antepartum period, hydralazine, 
with or without nitrates, is the vasodilator of choice and has 
been shown to reduce mortality.2,5,25,27-31,38 This is the second 
tier drug after ACEI/ARB in this regard during the post-
partum period.5,28 In severe cases, intravenous nitropruside, 
nitroglycerin, or nesiritide may be used.5,21,22,26,30,37,41 Nitro-
pruside should be avoided during the antepartum period 
due to the risk of fetal cyanide toxicity.5,29,30,37 Calcium 
channel blockers (CCB) were earlier avoided in heart fail-
ure because of their negative inotropic effect;2,5,37 a few re-
cent studies have shown that amlodipine improves survival 
and reduces interleukin-6 (IL-6) level in heart failure, indi-
cating a role in management of PPCM patients.2,5,37 Levosi-
mendan, a calcium sensitizer with vasodilator property, has 
successfully been used in PPCM patients. This results in 
the reduction of elevated pulmonary capillary wedge pres-
sure (PCWP) and improvement of ventricular dysfunction, 
thus allowing for earlier weaning from inotropes.43 Similar-
ly, beta blockers were also initially contraindicated in heart 
failure patients due to their negative inotropic properties. 
Recent studies have shown that beta blockers such as 
carvedilol actually improve outcome.2,5,28,37 Although beta 
blockers are associated with low birth weight babies, they 
are not absolutely contraindicated in pregnancy.37,55 Both 
beta blockers and ACEI have been shown to suppress im-
mune response in patients with PPCM.5,19,25,51 This may be 
beneficial considering the increased evidence for autoim-
mune etiology.2,5,25,28,56
Antiarrhythmic agents may be required for control of ar-
rythmias. No antiarrhythmic agent is fully safe in pregnan-
cy. Drugs with the highest safety profiles should be consid-
ered first.5,55 Digoxin and β-blockers have been used safely.55 
Though amiodarone is toxic during pregnancy, it can be 
considered in resistant arrhythmias when weighing the risks 
and benefits.55 Pacemakers and automated implantable car-
dioverter defibrillators (AICD) are options for refractory 
and life-threatening arrhythmias for those who have LVEF 
of less than 25% because of higher incidence of ventricular 
arrhythmias in this group of patients.2,5,9,20,23,28,31,37,51,55
The incidence of thromboembolism is reported to be 
very high in PPCM patients having LVEF < 35% and 
LVFS < 15% with atrial fibrillation,1,2,4,5,10,25,28,31,36,37 and pa-Severe Peripartum Cardiomyopathy Complicated with Pre-Eclampsia
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successfully used in patients with PPCM and found to have 
lower rate of failure, smaller drug requirement, easy titrabili-
ty with fewer hypotensive episodes (as it can be precisely ti-
trated), faster onset with excellent analgesia, and better pa-
tient satisfaction and postoperative pain score.5,12,26,37,42 Other 
disadvantages such as technical difficulty and post dural 
puncture headache (PDPH) may rarely be encountered when 
a 27-gauge pencil point spinal needle is used.26,61 Some anes-
thesiologists have successfully used continuous spinal anes-
thesia (CSA) for caesarian section in patients with severe 
PPCM.26,61 CSA has theoretical advantages over CSE in 
terms of rapid onset with precise titrability requiring less lo-
cal anesthetic, but it can be associated with higher incidence 
of PDPH and neurological complications.5,26,37,41,61 Avoidance 
of microcatheter and lignocaine has resulted in reduction of 
these complications.26,61 
Local anesthetic infiltration along with bilateral ilio-in-
guanal nerve block is a novel technique for cesarean sec-
tion with minimal hemodynamic effects.24 Unfamiliarity 
with the technique and higher incidence of failure are major 
obstacles to its routine implementation,5,26 but it can be con-
sidered in extreme cases. Although cesarean sections have 
been successfully conducted in PPCM patients with routine 
non-invasive monitoring,62 echocardiography and invasive 
parameters (IBP, CVP and/or PCWP) are usually moni-
tored during anesthesia.5,12,21,22,26,39,41,42,45,57,60-62 The benefits 
of invasive and advanced monitoring may outweigh all ar-
guments against it in severe cases. 
Postoperatively, these patients should be routinely moni-
tored in an ICU as they may require a ventilator, inotropic 
agents, and mechanical circulatory support due to a higher 
risk of congestive heart failure.5,9,12,21-23,28,39,41,42,61 Parenteral 
opioids or regional techniques are used to manage postopera-
tive pain.5,21,26,42,45 Anticoagulant should be restarted early in 
view of higher risk of thromboembolism.5,21 All preoperative 
medications should be resumed. Drugs with teratogenic po-
tential such as ACEI/ARBs and warfarin can be safely used 
after delivery and proper counseling for breast feeding.37
Prognosis of PPCM is related to presentation as well as 
to recovery of ventricular dysfunction.1-5,11 Though about 
30-50% recovery of ventricular dysfunction was reported 
earlier,1,4,5 currently 60-90% to even complete echocardio-
graphic recovery is reported if LVEF and LVESD on pre-
sentation is ≥ 27% and ≤ 5.5 cm.5,8-10,18,20,26,34,41,63 Basal level 
of NT-proBNP and IFN-γ may be a better predictor in this 
regard.49 Full recovery is documented by attainment of 
NYHA class I and LVEF of more than 50%.18,27,64 This re-
for labor analgesia in PPCM,5,41,61 combined spinal epidural 
(CSE) and continuous spinal analgesia (CSA) may be bet-
ter choices (the reasons for this are described later).5,26,41,42,61 
Forceps and vacuum devices should be used liberally to re-
duce the hemodynamic stress of 2nd stage of labour.29,37 Ce-
sarean section is mostly reserved for obstetric indications, but 
it may be considered in the case of a rapidly decompensating 
patient where maximum medical therapy fails.5,9,10,12,21,28,37,45,57 
These patients will need to be monitored in the ICU for the 
initial 2-3 postoperative or post-delivery days due to in-
creased risk of pulmonary edema caused by fluid overload 
and post-anesthetic cardiac dysfunction.5,6,12,20,35,37,44 NYHA 
class III or IV patients require ICU admission for aggres-
sive management with invasive monitoring, ionotropic, me-
chanical circulatory and ventilatory support, and ECMO for 
preoperative optimization.2,5,20-23,26,28,37,41,60,62 Apart from clas-
sical inotropes, inodilators like dobutamine, amrinone, mil-
rinone, enoximone and levosimendan may be beneficial in 
selective cases.5,22,29,30,37,59,60   
Cesarean sections in PPCM patients have been performed 
under general as well as regional anesthesia.21-24,26,39,41,42,45,57,62 
General anesthesia is mostly used in emergency surgery or 
when regional anesthesia is contraindicated,12,21,22,28,39,41,42 
and it offers the advantage of controlling airway and venti-
lation.5,26,42,61 But, hemodynamic stress from rapid sequence 
induction can be dangerous if opioids are not used to pre-
vent fetal respiratory depression.5,42 Though both inhalation 
and intravenous anesthesia have been used in PPCM cas-
es,21,22,39,41,42,45 both of these techniques can lead to materno-
fetal cardiorespiratory adverse effects which may some-
times require naloxone for reversal.22,39,41,42 Cardiac arrest 
following general anaesthesia in PPCM cases is also report-
ed.39,41 General anaesthesia adds to the already existing risk 
of thromboembolism.21 Vasodilators may be required to ac-
commodate the extra volume released from uterine auto-
transfusion after delivery of the fetus to prevent acute cardi-
ac failure and pulmonary edema.5,26 
Regional anesthesia on the other hand can be advantageous 
in PPCM because of sympatholysis-induced reduction of pre-
load and afterload.42,57,61,62 Single-shot spinal anesthesia is not 
recommended due to uncontrolled sympathetic blockade and 
acute hemodynamic instability which may precipitate an ad-
verse cardiac event including arrest.41,52 Carefully titrated epi-
dural anesthesia has been used in majority of cases because of 
its hemodynamic stability.41,42,57,62 The major disadvantages of 
this technique are failure or partial anesthesia which may lead 
to forced conversion to general anesthesia.26 CSE has been Pradipta Bhakta, et al.
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quent pregnancies.66 It is not fully clear, however, whether 
patients with improved cardiac function can safely become 
pregnant again.2,5 There remains the risk of further cardiac 
damage in subsequent pregnancies.2,5,9,25,28,37 Recently, one 
researcher found that even patients whose LVEF was nor-
malized (over 40%) after delivery still had a higher chance 
of recurrence and worsening heart failure in subsequent 
pregnancies if the baseline LVEF was less than 25%. Such 
patients should thus be strongly counseled against future 
pregnancies.17 Dobutamine stress tests have shown ventric-
ular contractile reserve to be severely impaired in patients 
showing echocardiographic normalization of cardiac dys-
function.67 Researchers strongly advise against future preg-
nancies for patients with persistent ventricular dysfunc-
tion.1,4,5,37 But with currently improved life expectancy and 
medical management, it may not be always justified to rule 
out further pregnancy in patients who recover full ventricu-
lar function.5,31,55,63 If unavoidable, subsequent pregnancies 
should always be managed by a multidisciplinary ap-
proach.2
Our case report once again supports the recently increas-
ing trend of PPCM in young primigravida. patient’s low 
body weight corroborates the average build of rural Indian 
population due to malnutrition and poor access to health 
care. Though cases occurring in last month of pregnancy 
are included in the classic category of PPCM, cases like 
ours presenting outside the time range are also categorized 
as PPCM in literature.9,11,12,21-26,39,41,45 The increased hemody-
namic load of twin pregnancy with superadded preeclamp-
sia resulted in earlier presentation in our patient. The ab-
sence of prior cardiac illness, typical clinical presentation, 
echocardiographic features, and the persistence of ventricu-
lar dysfunction after delivery confirmed the diagnosis of 
PPCM.1,2,4 Preeclampsia was diagnosed based on her pre-
senting BP (152/94 mmHg) and proteinuria (grade ++). Her 
high uric acid level also supported the diagnosis (Table 3).68 
Co-occurrence of preeclampsia and PPCM has been report-
ed in literature and is usually associated with higher mor-
bidity and mortality.1,4-20 In our patient, deranged LFT and 
coagulation parameters caused by the preeclampsia compli-
cated the severe heart failure. The obstetrician ruled out 
possibility of Hemolysis, Elevated liver enzymes, Low 
platelet count (HELLP) syndrome, as the laboratory param-
eters did not fit the classic picture. 
Though termination of pregnancy by cesarean section in 
PPCM is reserved for obstetric indications, it was done in our 
patient because of fetal death, rapid worsening of cardiac 
covery may take 1-2 years, as compared with the classic 
6-month time period.27 Those who have persistent LVEF of 
less than 40% at 3 months or less than 20% at 1-2 months 
after diagnosis and treatment fail to improve.51 Those with a 
baseline LVEF of 25% had the worst prognosis and a high-
er rate of requiring heart transplant for survival.17 This risk 
was also found not to be modified by subsequent recovery 
of LVEF after delivery. This specific group of patients may 
benefit from cardiac MRI, catheterization and endomyocar-
dial biopsy, and may need aphresis, immunoadsorption, in-
travenous gamma globulin, immunomodulation and anti-
viral therapy.27,51 Those who do recover have a good survival 
rate.4,5,25,35 Reduction of NT-proBNP and CRP level indi-
cates good recovery of ventricular function. These markers 
can be monitored to evaluate the prognosis of PPCM.65 The 
earlier 25-85% mortality rate was reported in patients with 
persistent or deteriorating cardiac dysfunction,1-5,28,38 and the 
current mortality rate has been reduced to about 0-9% in 
PPCM cases.5,7-10,15,25,27,28,31,32,35,37 The higher mortality in the 
past was probably due to diagnostic bias and lack of mod-
ern heart failure management technology.20 The current 
trend of improvement is due to advances in medical man-
agement.5,9,10,35,37 Comparatively higher mortality (10-30%) 
and lower rates of recovery of ventricular function (25-
35%) have been reported from Africa, Haiti, Turkey and the 
African-American population in USA.14,18,27,64 Race, ethnic-
ity, lack of advanced medical facilities, and lower socioeco-
nomic condition may play a role in this relatively poorer out-
come.14,15,20 A substantial number of these deaths could be 
prevented with modern medical care.20 Advanced age, mul-
tiparity, multiple gestation, African origin, African-Ameri-
can and Hispanic ethnic group, delayed postpartum presen-
tation, coexisting diseases, cardiac thrombus, higher QRS 
time, LVEDD, LVESD, pulmonary artery pressure, PCWP 
and reduced LVFS, LVEF, delay in management, higher 
basal level of NT-proBNP, IFN-γ, prolactin, TNF-α have 
been cited as poor prognostic criteria.1,4,5,10,18,20,25,27,29,31,49
Recurrence of PPCM in subsequent pregnancies is fre-
quently reported.1,4,5,25,27,38,66 PPCM patients with persistent 
ventricular dysfunction have a higher risk of mortality in 
future pregnancies.4,5,25,66 Fett, et al. found that 46% of pa-
tients who had LVEF of less than 55% before pregnancy 
had a relapse of heart failure in subsequent pregnancies, 
compared to only 17% relapse of heart failure in those who 
had LVEF of more than 55% before pregnancy. They sug-
gested that presenting LVEF during pregnancy may an im-
portant determinant for relapse of heart failure in subse-Severe Peripartum Cardiomyopathy Complicated with Pre-Eclampsia
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tropes. There was significant symptomatic improvement af-
ter effective onset of the block as seen by the decrease in 
severity of respiratory symptoms and some improvement in 
BP as well as SpO2 due to sympatholysis caused by region-
al anesthesia establishing its superiority in PPCM.26,42,57,61
Although newer inodilators are more effective for man-
aging biventricular failure,5,9,41 they were not available at 
our hospital, and a hypotensive state precluded their use. 
The epidural catheter was removed after the first top up 
dose under FFP cover as there was a plan to start DVT pro-
phylaxis as soon as the coagulation profile normalized.69 
Postoperative pain from cesarean section is not severe from 
the second postoperative day onwards, and can be managed 
by conventional analgesics.26 
Dyspnea on the second postoperative day was probably 
due to volume overload and worsening pathology of 
PPCM, which was resolved with furosemide and titration 
of inotropes, confirming our assumption and this was a typ-
ical feature of PPCM.12,21,39 Standard medical management 
of PPCM was resumed gradually when oral feeding was 
started. ACEI, spironolactone, carvedilol were added at ap-
propriate time. Although bromocriptine would have been a 
good choice considering the recent favorable evidence, it 
was not a good option in this patient due to the concern 
about depriving the neonate of breast milk. 
Elective termination of pregnancy resulted in improve-
ment in our patient’s clinical and laboratory parameters (Ta-
ble 3). However, worsening of her echocardiographic pa-
rameters indicates ongoing pathology resulting in persistent 
postoperative dysfunction. She required insertion of a pace-
maker due to persistent bradyarrhythmia, which further 
supports the higher incidence of malignant arrhythmias in 
these patients.20 Our case report strengthens the association 
of bad prognosis in patients with PPCM with multiple ges-
tation, associated preeclampsia presenting with  low LVEF 
and PAH. 
However, as a single patient case report does not carry 
much scientific weight, we decided to report, as it shows, 
that CSE approach with sufentanil as a neuraxial opioid can 
be a safe choice for anesthesia in this delicate subgroup of 
pregnant patients, if planned properly. 
CONCLUSION
Anesthetic management of a patient with PPCM should be 
comprised of adequate preoperative optimization using a 
failure and deteriorating laboratory parameters. A multidisci-
plinary approach was taken for preoperative optimization 
with standard management of cardiac failure and correction 
of coagulation parameters as per  literature.2,5,8,12,21,28,37,42 Hep-
arin was not started preoperatively as the patient’s coagula-
tion profile was deranged. ACEI was avoided in antepartum 
period for obvious reasons of teratogenecity. 
We did not preload the patient prior to CSE as we were 
monitoring the CVP to avoid fluid overload. Although co-
agulopathy is a relative contraindication for regional anes-
thesia, the deranged coagulation parameters were corrected 
and specific precautions were taken as per standard guide-
lines before performing CSE.69
A low dosage of intrathecal bupivacaine was used to 
avoid excessive hypotension and associated complications.   
We used a slightly higher dosage of intrathecal sufentanil to 
reduce local anaesthetic requirement and to provide pro-
longed analgesia, and our patient did not require any epidu-
ral top-ups during the surgery.70 This may be advantageous 
as compared to the use of intrathecal fentanyl, where fre-
quent top ups were required.26,42 This has helped us to avoid 
epidural-induced hypotension, which would have required 
vasopressor for management of its adverse consequences in 
a already cardiac compromised patient.12 Prolonged dura-
tion of analgesia seen with neuraxial sufentanil may be be-
cause of its higher potency and affinity to opioid receptors.71 
No major materno-fetal cardiorespiratory complications oc-
curred, as evidenced by the stable intraoperative vital pa-
rameters and the Apgar scores of the fetus. The patient com-
plained of mild itching, which responded appropriately to 
antihistaminic. Though there are reports of use of intrathe-
cal fentanyl in PPCM patients,26,42 use of sufentanil as an 
intrathecal opioid for CSE in PPCM patients has not been 
reported to date. In our patient, subarachonoid block with 
bupivacaine plus sufentanil was sufficient for operation and 
resulted in excellent postoperative analgesia for up to six 
hours. Physiological changes due to severe PPCM might 
have altered the pharmacokinetics and pharmacodynamics 
of the spinally administered drugs prolonging their duration 
of action. Therefore, we feel that sufentanil as an additive in 
CSE may be more advantageous for anesthesia as well as 
postoperative pain relief in PPCM patients. More studies 
are needed to clarify this issue.
Furosemide was used prophylactically to prevent fluid 
overload from uterine auto transfusion.41 Vasodilator infu-
sion is also recommended at this stage,5,21,26 but this was not 
possible in our case because the patient was already on ino-Pradipta Bhakta, et al.
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